Ubs Group Ag Genfit S.A. Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GNFT
# of Institutions
8Shares Held
49.2KCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY32.8KShares$180,5290.0% of portfolio
-
Old Mission Capital LLC12.8KShares$70,6210.0% of portfolio
-
Optiver Holding B.V. Amsterdam, P72.24KShares$12,3580.0% of portfolio
-
Rhumbline Advisers Boston, MA678Shares$3,7350.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ273Shares$1,5040.0% of portfolio
About Genfit S.A.
- Ticker GNFT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,815,500
- Market Cap $274M
- Description
- Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...